{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T06:09:10Z","timestamp":1777961350507,"version":"3.51.4"},"reference-count":36,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.medcli.2016.05.023","type":"journal-article","created":{"date-parts":[[2016,8,9]],"date-time":"2016-08-09T23:40:42Z","timestamp":1470786042000},"page":"287-292","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Uso del tratamiento hormonal sustitutivo en Espa\u00f1a: tendencias en el per\u00edodo 2000-2014"],"prefix":"10.1016","volume":"147","author":[{"given":"Laura","family":"Balad\u00e9 Mart\u00ednez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dolores","family":"Montero Corominas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"Mac\u00edas Saint-Gerons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2016.05.023_bib0185","first-page":"CD004143","article-title":"Long term hormone therapy for perimenopausal and postmenopausal women","volume":"7","author":"Marjoribanks","year":"2012","journal-title":"Cochrane Database Syst Rev."},{"key":"10.1016\/j.medcli.2016.05.023_bib0190","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/S0025-7753(02)73296-X","article-title":"Tratamiento hormonal sustitutivo en Espa\u00f1a. Un estudio de utilizaci\u00f3n","volume":"119","author":"Benet Rodr\u00edguez","year":"2002","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.medcli.2016.05.023_bib0195","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results From the Women's Health Initiative randomized controlled trial","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA."},{"key":"10.1016\/j.medcli.2016.05.023_bib0200","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1001\/jama.291.14.1701","article-title":"Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial","volume":"291","author":"Anderson","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.medcli.2016.05.023_bib0205","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0140-6736(03)14596-5","article-title":"Breast cancer and hormone-replacement therapy in the Million Women Study","volume":"362","author":"Beral","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.medcli.2016.05.023_bib0210","unstructured":"U. S. Food and Drug Administration. FDA new release: FDA updates hormone therapy information for post menopausal women [consultado 28 Jun 2016]. Disponible en: http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/2004\/ucm108243.htm"},{"key":"10.1016\/j.medcli.2016.05.023_bib0215","doi-asserted-by":"crossref","first-page":"104","DOI":"10.7326\/0003-4819-157-2-201207170-00466","article-title":"Menopausal hormone therapy for the primary prevention of chronic conditions: A systematic review to update the U. S. Preventive Services Task Force recommendations","volume":"157","author":"Nelson","year":"2012","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.medcli.2016.05.023_bib0220","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/tbj.12001","article-title":"Hormone therapy use and breast cancer incidence by histological subtypes in Sweden and Norway","volume":"18","author":"Suhrke","year":"2012","journal-title":"Breast J."},{"key":"10.1016\/j.medcli.2016.05.023_bib0225","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1097\/GME.0000000000000487","article-title":"Hormonal contraception and postmenopausal hormone therapy in Spain: Time trends and patterns of use","volume":"22","author":"Costas","year":"2015","journal-title":"Menopause."},{"key":"10.1016\/j.medcli.2016.05.023_bib0230","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1097\/AOG.0000000000000469","article-title":"Trends of postmenopausal estrogen plus progestin prevalence in the United States between 1970 and 2010","volume":"124","author":"Jewett","year":"2014","journal-title":"Obstet Gynecol."},{"key":"10.1016\/j.medcli.2016.05.023_bib0235","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/AOG.0b013e318265df42","article-title":"A sustained decline in postmenopausal hormone use: Results from the National Health and Nutrition Examination Survey, 1999-2010","volume":"120","author":"Sprague","year":"2012","journal-title":"Obstet Gynecol."},{"key":"10.1016\/j.medcli.2016.05.023_bib0240","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/pds.1273","article-title":"Changes in pattern of use, clinical characteristics and persistence rate of hormone replacement therapy among postmenopausal women after the WHI publication","volume":"16","author":"Guay","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"10.1016\/j.medcli.2016.05.023_bib0245","doi-asserted-by":"crossref","first-page":"641","DOI":"10.5694\/j.1326-5377.2008.tb01821.x","article-title":"Decrease in breast cancer incidence following a rapid fall in use of hormone replacement therapy in Australia","volume":"188","author":"Canfell","year":"2008","journal-title":"Med J Aust."},{"key":"10.1016\/j.medcli.2016.05.023_bib0250","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1097\/gme.0b013e3181a02b44","article-title":"Trends in hormone therapy use before and after publication of the Women's Health Initiative trial: 10 years of follow-up","volume":"16","author":"Barbaglia","year":"2009","journal-title":"Menopause"},{"key":"10.1016\/j.medcli.2016.05.023_bib0255","doi-asserted-by":"crossref","first-page":"247","DOI":"10.4321\/S1135-57272013000300004","article-title":"Evoluci\u00f3n del uso de medicamentos ansiol\u00edticos e hipn\u00f3ticos en Espa\u00f1a durante el per\u00edodo 2000-2011","volume":"87","author":"Vicente S\u00e1nchez","year":"2013","journal-title":"Rev Esp Salud Publica"},{"key":"10.1016\/j.medcli.2016.05.023_bib0260","unstructured":"Consejo General de Colegios Oficiales de Farmac\u00e9uticos (CGCOF). Cat\u00e1logo de especialidades farmac\u00e9uticas 2000 a 2014. Madrid: CGCOF."},{"key":"10.1016\/j.medcli.2016.05.023_bib0265","doi-asserted-by":"crossref","first-page":"e0117628","DOI":"10.1371\/journal.pone.0117628","article-title":"Time trends of period prevalence rates of patients with inhaled long-acting beta-2-agonists-containing prescriptions: A European comparative database study","volume":"10","author":"Rottenkolber","year":"2015","journal-title":"PLoS One."},{"key":"10.1016\/j.medcli.2016.05.023_bib0270","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1136\/bmj.329.7471.868","article-title":"The scandal of poor epidemiological research","volume":"329","author":"Von Elm","year":"2004","journal-title":"BMJ."},{"key":"10.1016\/j.medcli.2016.05.023_bib0275","unstructured":"Agencia Espa\u00f1ola del Medicamento. Comunicaci\u00f3n sobre riesgos de medicamentos para profesionales sanitarios. Ref. 2002\/07, 11 de julio de 2002. Riesgos y beneficios del tratamiento hormonal sustitutivo con estr\u00f3genos asociados a progest\u00e1genos: nuevos datos. [consultado 28 Jun 2016]. Disponible en: http:\/\/www.aemps.gob.es\/informa\/notasInformativas\/medicamentosUsoHumano\/seguridad\/2002\/docs\/THS-estrogenos-progestagenos_PS.pdf"},{"key":"10.1016\/j.medcli.2016.05.023_bib0280","unstructured":"Informaci\u00f3n de la Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios para el profesional sanitario. Restricci\u00f3n de las indicaciones terap\u00e9uticas de la terapia hormonal de sustituci\u00f3n. 23 de enero de 2004. [consultado 28 Jun 2016]. Disponible en: http:\/\/www.aemps.gob.es\/informa\/notasInformativas\/medicamentosUsoHumano\/seguridad\/2004\/docs\/NI_2004-01_THS_restriccion.pdf"},{"key":"10.1016\/j.medcli.2016.05.023_bib0285","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1258\/175404507783004285","article-title":"Changes in practice since the publication in 2007 of further results from the Women's Health Initiative and the Million Women Study","volume":"13","author":"Cust","year":"2007","journal-title":"Menopause Int."},{"key":"10.1016\/j.medcli.2016.05.023_bib0290","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1001\/jama.280.7.605","article-title":"Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women","volume":"280","author":"Hulley","year":"1998","journal-title":"JAMA."},{"key":"10.1016\/j.medcli.2016.05.023_bib0295","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/ijc.25314","article-title":"Menopausal hormone therapy and breast cancer risk: Impact of different treatments","volume":"128","author":"Bakken","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1016\/j.medcli.2016.05.023_bib0300","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1097\/GME.0000000000000546","article-title":"Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society","volume":"22","year":"2015","journal-title":"Menopause."},{"key":"10.1016\/j.medcli.2016.05.023_bib0305","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. Octubre 2008. Nota informativa sobre terapia hormonal en la menopausia: actualizaci\u00f3n de la informaci\u00f3n. Comunicaci\u00f3n sobre riesgos de medicamentos para profesionales sanitarios. Ref. 2008\/16. [consultado 28 Jun 2016]. Disponible en: http:\/\/www.aemps.gob.es\/informa\/notasInformativas\/medicamentosUsoHumano\/seguridad\/2008\/NI_2008-16_terapia_hormonal.htm"},{"key":"10.1016\/j.medcli.2016.05.023_bib0310","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/ajhb.20121","article-title":"Age at natural menopause in Spain and the United States: Results from the DAMES project","volume":"17","author":"Reynolds","year":"2005","journal-title":"Am J Hum Biol."},{"key":"10.1016\/j.medcli.2016.05.023_bib0315","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1056\/NEJMsr070105","article-title":"The decrease in breast-cancer incidence in 2003 in the United States","volume":"356","author":"Ravdin","year":"2007","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2016.05.023_bib0320","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/j.ejca.2009.01.016","article-title":"Is the recent fall in incidence of post-menopausal breast cancer in UK related to changes in use of hormone replacement therapy","volume":"45","author":"Parkin","year":"2009","journal-title":"Eur J Cancer."},{"key":"10.1016\/j.medcli.2016.05.023_bib0325","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1097\/MLR.0b013e31818bfe9b","article-title":"Hormone replacement therapy and cardiovascular health in the United States","volume":"47","author":"Shetty","year":"2009","journal-title":"Med Care"},{"key":"10.1016\/j.medcli.2016.05.023_bib0330","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1093\/jnci\/djq345","article-title":"Breast cancer incidence and hormone replacement therapy in Canada","volume":"102","author":"De","year":"2010","journal-title":"J Natl Cancer Inst."},{"key":"10.1016\/j.medcli.2016.05.023_bib0335","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1093\/jnci\/djp358","article-title":"Recent changes in breast cancer incidence in Spain 1980-2004","volume":"101","author":"Poll\u00e1n","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.medcli.2016.05.023_bib0340","first-page":"E1","article-title":"Changes by age in breast cancer incidence, mammography screening and hormone therapy use in France from 2000 to 2006","volume":"96","author":"S\u00e9radour","year":"2009","journal-title":"Bull Cancer."},{"key":"10.1016\/j.medcli.2016.05.023_bib0345","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1186\/1471-2407-14-874","article-title":"Breast and prostate cancer: An analysis of common epidemiological features in mortality trends in Spain","volume":"14","author":"L\u00f3pez-Abente","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.medcli.2016.05.023_bib0350","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/bcr2463","article-title":"Recent declines in breast cancer incidence: Mounting evidence that reduced use of menopausal hormones is largely responsible","volume":"12","author":"Banks","year":"2010","journal-title":"Breast Cancer Res."},{"issue":"Suppl 1","key":"10.1016\/j.medcli.2016.05.023_bib0355","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.1016\/j.canep.2015.08.003","article-title":"European Code against Cancer 4th Edition: Medical exposures, including hormone therapy, and cancer","volume":"39","author":"Friis","year":"2015","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.medcli.2016.05.023_bib0360","series-title":"BIFAP: Base de datos para la investigaci\u00f3n farmacoepidemiol\u00f3gica en Atenci\u00f3n Primaria","author":"Bonis Sanz","year":"2016"}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775316301774?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775316301774?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T15:47:35Z","timestamp":1657036055000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775316301774"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":36,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["S0025775316301774"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2016.05.023","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Uso del tratamiento hormonal sustitutivo en Espa\u00f1a: tendencias en el per\u00edodo 2000-2014","name":"articletitle","label":"Article Title"},{"value":"Medicina Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medcli.2016.05.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}